Dissertation Direct Genome Editing of Patient-Derived Xenografts Using CRISPR-Cas9 Enables Rapid in vivo Functional Genomics (2019) Mentor Charles M. Rudin, MD, PhD End Year 2019 Education BS, Northeastern University Current Title & Affiliations Research Scientist, C4 Therapeutics Inc. Publications Wohlhieter CA, Richards AL, Uddin F, Hulton CH, Quintanal-Villalonga À, Martin A, de Stanchina E, Bhanot U, Asher M, Shah NS, Hayatt O, Buonocore DJ, Rekhtman N, Shen R, Arbour KC, Donoghue M, Poirier JT, Sen T, Rudin CM. (2020) Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer. Cell Rep. Hulton, C.H., Costa, E.A., Shah, N.S. et al. Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid in vivo functional genomics. (2020) Nat Cancer 1, 359–369 (2020). doi.org/10.1038/s43018-020-0040-8 View a full listing of Christopher Hulton’s journal articles.
